Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671169 | 0.89 | ADORA2A (0.40) | MAPK14ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5671842 | 0.86 | MAPK14 (0.46) | MAPK14ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5672313 | 0.86 | ADORA2A (0.50) | MAPK14ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5672358 | 0.86 | MAPK14 (0.46) | MAPK14ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5673357 | 0.84 | ADORA2A (0.41) | MAPK14ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL7362751 | 0.78 | MAPK14 (0.42) | MAPK14ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5671138 | 0.78 | MAPK14 (0.48) | MAPK14ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5671819 | 0.76 | ADORA2A (0.45) | MAPK14ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5673482 | 0.76 | CREBBP (0.44) | MAPK14ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5671140 | 0.76 | GRM2 (0.42) | MAPK14ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030121-B2 | Pyrazolopyrazine compound and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040152706-A1 | Pyrazolopyrazine compound pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152706-A1 | Pyrazolopyrazine compound pharmaceutical use thereof | ADORA2A, P2RX5, ADORA1 | MAPK14 2567/4885ADORA2A 1/4885ADORA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.